Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Jazz Pharmaceuticals plc

NASDAQ: JAZZ · Life Sciences · 12 alerts · CIK 1232524

Share price
$239.77Close, Nov 16
Market cap
$15.4B
Shares outstanding
64.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jazz Pharmaceuticals plc filings on SEC EDGAR ↗

4:08 PM ET 8-K
Financial Results

Jazz Pharmaceuticals Financial Results

Jazz Pharmaceuticals reported record third-quarter 2026 revenues of $1.2 billion, a 10% increase year-over-year, driven by strong performance from Xywav and the launch of Ziihera. The company raised its full-year 2026 revenue guidance to a range of $4.775 billion to $4.85 billion and highlighted the closing of its acquisition of Actio Biosciences.

“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance. At the same time, we continue to strengthen the drivers of our future growth, with the approval and rapid launch of Ziihera in first-line HER2-positive GEA and the acquisition of Actio, which adds ABS-1230 and deepens our pipeline in rare, refractory epilepsies. Jazz is moving with momentum and urgency to advance practice-changing medicines that deliver meaningful benefit for patients and durable value for shareholders.”

Renee Gala, president and chief executive officer of Jazz Pharmaceuticals

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.